Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1
Pramod K. Mistry(Yale University), Michel Peterschmitt, Gregory M. Pastores(New York University), Suma P. Shankar(Emory University), Seymour Packman(University of California, San Francisco), Majed Dasouki(University of Kansas), Atul Mehta(National Health Service), Leorah Ross, Manisha Balwani(Icahn School of Medicine at Mount Sinai), Marwan Ghosn(Hôtel-Dieu de France), Hadhami Ben Turkia(Hôpital La Rabta), Elena Lukina(National Medical Research Center for Hematology), Sumita Danda(Christian Medical College & Hospital), Sarit Assouline(Jewish General Hospital), Jennifer Angell, Dominick Amato(Mount Sinai Hospital), Andres Ortega, María Helena Solano(Fundación Universitaria de Ciencias de la Salud), Evgueniy Hadjiev(Alexandrovska Hospital), Hagit Baris(Tel Aviv University), Мilan Petakov(University of Belgrade)
Cited by 156
Related Papers
Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper–transporting ATPase
|Nature Genetics|1993|1.4k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555